Early Evaluation of Tumor Response to Chemotherapy
Author Information
Author(s): Brock C S, Young H, O'Reilly S M, Matthews J, Osman S, Evans H, Newlands E S, Price P M
Primary Institution: CRC-PET Oncology Group, MRC Cyclotron Unit, Hammersmith Campus, Imperial College of Science and Medicine
Hypothesis
Can quantitation of metabolic rate of glucose (MRGlu) provide an objective measure of early subclinical response to chemotherapy in recurrent high-grade gliomas?
Conclusion
MRGlu is a more sensitive measure of response to chemotherapy than traditional methods.
Supporting Evidence
- Nine patients were assessed with PET scans before and after treatment.
- Responders had a greater than 25% reduction in MRGlu.
- MRGlu was found to be a more sensitive discriminator of response than static SUV analysis.
Takeaway
This study looked at how well a special scan can tell if a brain tumor is getting better after treatment. It found that the scan is really good at showing changes.
Methodology
Patients underwent PET scans before and after treatment to measure MRGlu.
Limitations
The study had a small sample size and did not correlate whole tumor changes in MRGlu with response.
Participant Demographics
Patients with recurrent high-grade gliomas receiving temozolomide.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website